Concepedia

A phase II trial of ganetespib, a heat shock protein 90 Hsp90) inhibitor, in patients with docetaxel-pretreated metastatic castrate-resistant prostate cancer (CRPC)-a prostate cancer clinical trials consortium (PCCTC) study

Manish Thakur, Lance K. Heilbrun, Shijie Sheng, Mark N. Stein, Glenn Liu, Emmanuel S. Antonarakis, Ulka N. Vaishampayan, Sijana H. Dzinic, Xiaohua Li, Stacy Freeman,

Investigational New Drugs · 2015 · 57 citations · 23 references

References

23

Optimal two-stage designs for phase II clinical trials

Richard Simon · Controlled Clinical Trials · 1989 · 3.6K citations

Public Health, Biostatistics, Experimental Design +10

Statistical Methods for Survival Data Analysis.

Peter A. Lachenbruch, Elisa T. Lee · Journal of the American Statistical Association · 1993 · 2.9K citations

Public Health, Biostatistics, Survival Analysis +11

17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts.

David B. Solit, Fuzhong F. Zheng, Pamela N. Münster et al. · PubMed · 2002 · 435 citations

Medicine, Oncology, Pharmacology +17

Ganetespib, a Unique Triazolone-Containing Hsp90 Inhibitor, Exhibits Potent Antitumor Activity and a Superior Safety Profile for Cancer Therapy

Weiwen Ying, Zhenjian Du, Lijun Sun et al. · Molecular Cancer Therapeutics · 2011 · 231 citations

Medicine, Oncology, Pharmacology +11

A Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Hormone-Refractory Metastatic Prostate Cancer

Elisabeth I. Heath, David W. Hillman, Ulka N. Vaishampayan et al. · Clinical Cancer Research · 2008 · 186 citations · Full text

Medicine, Oncology, Pharmacology +16